Search results for "TUMORS"

showing 10 items of 1138 documents

Reciprocal influence of B cells and tumor macro and microenvironments in the ApcMin/+ model of colorectal cancer

2017

One of the most fascinating aspects of the immune system is its dynamism, meant as the ability to change and readapt according to the organism needs. Following an insult, we assist to the spontaneous organization of different immune cells which cooperate, locally and at distance, to build up an appropriate response. Throughout tumor progression, adaptations within the systemic tumor environment, or macroenvironment, result in the promotion of tumor growth, tumor invasion and metastasis to distal organs, but also to dramatic changes in the activity and composition of the immune system. In this work, we show the changes of the B-cell arm of the immune system following tumor progression in the…

lcsh:Immunologic diseases. Allergy0301 basic medicineColorectal cancerImmunologySpleenintestinal cancerBiologylcsh:RC254-282Metastasis03 medical and health sciencesImmune systemPeritoneummedicineImmunology and Allergyapcmin/+ miceApcMin/+mice; B lymphocytes; IgA; IL-10; intestinal cancer; Immunology and Allergy; Immunology; OncologyB lymphocyteApcMin/+micelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePhenotypeInterleukin 10030104 developmental biologymedicine.anatomical_structureOncologyTumor progressionIL-10Immunologyb lymphocyteslcsh:RC581-607IgAOncoImmunology
researchProduct

Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study

2017

IF 7.719; International audience; Introduction: Some studies have suggested that baseline tumor-infiltrating-lymphocytes (TILs), such as CD8+ and FoxP3+ T-cells, may be associated with a better prognosis in colorectal cancer. We sought to investigate modulation of the immune response by preoperative radiotherapy (preopRT) and its impact on survival in locally advanced rectal cancer (LARC). Materials & Methods: We analyzed data for 237 patients with LARC who received RT. Density of TILS (CD8+ and FoxP3+) in intraepithelial (iTILs) and stromal compartments (sTILs) were evaluated from surgery pathological specimens and biopsies performed at baseline. The primary endpoint was to assess the impa…

lcsh:Immunologic diseases. Allergy0301 basic medicineOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentImmunology[SDV.CAN]Life Sciences [q-bio]/Cancerchemical and pharmacologic phenomenalcsh:RC254-282radiation therapy[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointImmunology and Allergyrectal cancertranslational studyOriginal ResearchUnivariate analysisbusiness.industryTumor-infiltrating lymphocytesDose fractionationFOXP3hemic and immune systemslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease3. Good healthRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesistumor-infiltrating lymphocyteslcsh:RC581-607businessAdjuvant
researchProduct

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

2018

Purpose: While recent studies described the role of IKZF1/3 proteins in multiple myeloma (MM) cells, few have highlighted the significance of IKZF1/3 expression in T-cells. In this study we examine the prognostic and predictive value of IKZF1/3 expression in T-cells in patients with MM stage III. Experimental design: We analysed the IKZF1/3 expression levels in T-cells from 45 MM stage I (MMI) and 50 newly diagnosed MM stage III (MMIII) patients, according to Durie-Salmon staging system, by flow cytometry to examine their prognostic and predictive value. We also combined in vivo observations with in vitro assays to determine the effect of IKZF1/3 expression on the T-cell immunophenotype and…

lcsh:Immunologic diseases. Allergy0301 basic medicineOncologymedicine.medical_specialtyImmunologyMedizinlcsh:RC254-282Flow cytometry03 medical and health sciencesikzf10302 clinical medicineImmunophenotypingikzf3immunomodulatory drugsIn vivoInternal medicinemedicineImmunology and AllergyStage (cooking)t cellsMultiple myelomaOriginal ResearchLenalidomidemedicine.diagnostic_testbusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePomalidomidemultiple myelomaThalidomide030104 developmental biologyOncologybiomarker trialsimmunelcsh:RC581-607business030215 immunologymedicine.drug
researchProduct

Trial Watch: Adoptively transferred cells for anticancer immunotherapy

2017

IF 7.719; International audience; Immunotherapies aimed at strengthening immune effector responses against malignant cells are growing at exponential rates. Alongside, the impressive benefits obtained by patients with advanced melanoma who received adoptively transferred tumor-infiltrating lymphocytes (TILs) have encouraged the scientific community to pursue adoptive cell transfer (ACT)-based immunotherapy. ACT involves autologous or allogenic effector lymphocytes that are generally obtained from the peripheral blood or resected tumors, expanded and activated ex vivo, and administered to lymphodepleted patients. ACT may be optionally associated with chemo- and/or immunotherapeutics, with th…

lcsh:Immunologic diseases. Allergy0301 basic medicinePD-L1Adoptive cell transferBreakthrough therapymedicine.medical_treatmentImmunology[SDV.CAN]Life Sciences [q-bio]/CancerReviewBiologycytotoxic T lymphocytelcsh:RC254-282CD19[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineAntigenPD-L1PD-1medicineImmunology and AllergyCytotoxic T cellNK cellchimeric antigen receptorImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChimeric antigen receptor3. Good healthimmune checkpoint blockers030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologybiology.proteinlcsh:RC581-607
researchProduct

A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets.

2018

International audience; NKp46 (CD335) is a surface receptor shared by both human and mouse natural killer (NK) cells and innate lymphoid cells (ILCs) that transduces activating signals necessary to eliminate virus-infected cells and tumors. Here, we describe a spontaneous point mutation of cysteine to arginine (C14R) in the signal peptide of the NKp46 protein in congenic Ly5.1 mice and the newly generated NCR(B6C14R) strain. Ly5.1(C14R) NK cells expressed similar levels of Ncr1 mRNA as C57BL/6, but showed impaired surface NKp46 and reduced ability to control melanoma tumors in vivo. Expression of the mutant NKp46(C14R) in 293T cells showed that NKp46 protein trafficking to the cell surface …

lcsh:Immunologic diseases. Allergy0301 basic medicineSignal peptideintracellular traffickingImmunologyCellCongenicinnate lymphoid cellsBiologymedicine.disease_causelcsh:RC254-28203 medical and health sciences0302 clinical medicinemedicineImmunology and Allergyddc:610congenic miceReceptorOriginal ResearchMutationEndoplasmic reticulumInnate lymphoid cellHEK 293 cellslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCell biology030104 developmental biologymedicine.anatomical_structureOncologyactivation receptors[SDV.IMM]Life Sciences [q-bio]/Immunologylcsh:RC581-607030215 immunology
researchProduct

Bovine herpesvirus 4-based vector delivering the full length xCT DNA efficiently protects mice from mammary cancer metastases by targeting cancer ste…

2018

Despite marked advancements in its treatment, breast cancer is still the second leading cause of cancer death in women, due to relapses and distal metastases. Breast cancer stem cells (CSCs), are a cellular reservoir for recurrence, metastatic evolution and disease progression, making the development of novel therapeutics that target CSCs, and thereby inhibit metastases, an urgent need. We have previously demonstrated that the cystine-glutamate antiporter xCT (SLC7A11), a protein that was shown to be overexpressed in mammary CSCs and that plays a key role in the maintenance of their redox balance, self-renewal and resistance to chemotherapy, is a potential target for mammary cancer immunoth…

lcsh:Immunologic diseases. Allergy0301 basic medicinecancer stem cellmedicine.medical_treatmentImmunologylcsh:RC254-28203 medical and health sciences0302 clinical medicineBreast cancerCancer immunotherapyCancer stem cellbovine herpesvirus 4-based vector; cancer stem cell; immunotherapy; Mammary cancer; xCT; Immunology and Allergy; Immunology; OncologymedicineImmunology and Allergybovine herpesvirus 4-based vectorOriginal ResearchAntibody-dependent cell-mediated cytotoxicitybusiness.industryxCTCancerImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMetastatic breast cancer030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchMammary cancerimmunotherapyStem celllcsh:RC581-607businessOncoImmunology
researchProduct

Evolution of melanoma cross-resistance to CD8⁺ T cells and MAPK inhibition in the course of BRAFi treatment

2018

The profound but frequently transient clinical responses to BRAFV600 inhibitor (BRAFi) treatment in melanoma emphasize the need for combinatorial therapies. Multiple clinical trials combining BRAFi and immunotherapy are under way to further enhance therapeutic responses. However, to which extent BRAFV600 inhibition may affect melanoma immunogenicity over time remains largely unknown. To support the development of an optimal treatment protocol, we studied the impact of prolonged BRAFi exposure on the recognition of melanoma cells by T cells in different patient models. We demonstrate that autologous CD8+ tumor-infiltrating lymphocytes (TILs) efficiently recognized short-term (3, 7 days) BRAF…

lcsh:Immunologic diseases. Allergy0301 basic medicinecd8+ t cellsmedicine.medical_treatmentT cellImmunologyMedizinlcsh:RC254-282mekresistance03 medical and health sciences0302 clinical medicineAntigenantigensmelanomaImmunology and AllergyMedicineCytotoxic T cellbusiness.industryMelanomaImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseTumor antigeninhibitor030104 developmental biologymedicine.anatomical_structureOncologyCSPG4030220 oncology & carcinogenesisCancer researchlcsh:RC581-607businessbrafCD8
researchProduct

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refract…

2018

ABSTRACT We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM). Patients with relapsed/refractory solid tumors not amenable to standard therapy received solitomab as continuous IV infusion in a phase 1 dose-escalation study with six different dosing schedules. The primary endpoint was frequency and severity of adverse events (AEs). Secondary endpoints included pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. Sixty-five patients received solitomab at doses between 1 and 96 µg/day for ≥28 days. Fifteen patients had dose-limiting toxicities (DLTs): e…

lcsh:Immunologic diseases. Allergy0301 basic medicinemedicine.medical_specialtyImmunologyAMG 110bispecificlcsh:RC254-282Gastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSolitomabRefractoryPharmacokineticsInternal medicineImmunology and AllergyMedicineAdverse effectOriginal Researchbusiness.industryEpCAM phase 1Epithelial cell adhesion moleculesolitomablcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensBiTE®CD3Discontinuation030104 developmental biologyMT110OncologyTolerabilitychemistry030220 oncology & carcinogenesisPharmacodynamicssolid tumorimmunotherapylcsh:RC581-607businessOncoimmunology
researchProduct

Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models.

2018

Immune checkpoint blockade (ICB) is currently evaluated in patients with glioblastoma (GBM), based on encouraging clinical data in other cancers, and results from studies with the methylcholanthrene-induced GL261 mouse glioma. In this paper, we describe a novel model faithfully recapitulating some key human GBM characteristics, including low mutational load, a factor reported as a prognostic indicator of ICB response. Consistent with this observation, SB28 is completely resistant to ICB, contrasting with treatment sensitivity of the more highly mutated GL261. Moreover, SB28 shows features of a poorly immunogenic tumor, with low MHC-I expression and modest CD8(+) T-cell infiltration, suggest…

lcsh:Immunologic diseases. Allergy0301 basic medicinemedicine.medical_treatmentGL261ImmunologyOncology and CarcinogenesisMajor histocompatibility complexMalignancylcsh:RC254-282Mutational loadVaccine Related03 medical and health sciences0302 clinical medicineRare DiseasesGliomamedicineImmunology and Allergyddc:576.5sb28mutational loadCancerddc:616biologybusiness.industryBrief ReportSB28glioblastomaNeurosciencesImmunotherapyimmune checkpoint blockadelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmune checkpointBlockadeBrain DisordersBrain Cancer030104 developmental biologyOncologygl261030220 oncology & carcinogenesisCancer researchbiology.proteinImmunizationlcsh:RC581-607businessGlioblastomaCD8Immune checkpoint blockadeGlioblastoma
researchProduct

Hazardous air pollutants and primary liver cancer in Texas.

2016

The incidence of hepatocellular carcinoma (HCC), the most common primary liver cancer, is increasing in the US and tripled during the past two decades. The reasons for such phenomenon remain poorly understood. Texas is among continental states with the highest incidence of liver cancer with an annual increment of 5.7%. Established risk factors for HCC include Hepatitis B and C (HBV, HCV) viral infection, alcohol, tobacco and suspected risk factors include obesity and diabetes. While distribution of these risk factors in the state of Texas is similar to the national data and homogeneous, the incidence of HCC in this state is exceptionally higher than the national average and appears to be di…

lcsh:Medicine010501 environmental sciences01 natural sciencesGeographical locations0302 clinical medicineRisk FactorsEpidemiology of cancerMedicine and Health SciencesMedicineOrganic Chemicalslcsh:Scienceeducation.field_of_studyAir PollutantsPrincipal Component AnalysisMultidisciplinaryOrganic CompoundsIncidence (epidemiology)IncidenceLiver DiseasesLiver NeoplasmsHepatitis BTexasPollutionChemistryOncology030220 oncology & carcinogenesisPhysical SciencesEngineering and TechnologyLiver cancerEnvironmental MonitoringResearch ArticlePollutantsCarcinoma HepatocellularEnvironmental EngineeringPopulationGastroenterology and HepatologyXylenesCarcinomas03 medical and health sciencesEnvironmental healthAir PollutionAromatic HydrocarbonsGastrointestinal TumorsHumansEnvironmental ChemistryRisk factoreducation0105 earth and related environmental sciencesbusiness.industrylcsh:REcology and Environmental SciencesOrganic ChemistryChemical CompoundsCancerCancers and NeoplasmsBenzeneEnvironmental ExposureHepatocellular Carcinomamedicine.diseaseUnited StatesHydrocarbonsCancer registryNorth Americalcsh:QHydrochloric AcidPeople and placesbusinessAcidsToluenePloS one
researchProduct